MediLink Therapeutics (Suzhou) Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MediLink Therapeutics (Suzhou) Co. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
MediLink Therapeutics (Suzhou) Co.: 7 sponsored US clinical trials, 6 recruiting.
MediLink Therapeutics (Suzhou) Co. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 3 trials.
Upper-quartile sponsor footprint
MediLink Therapeutics (Suzhou) Co. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352
A Study of YL201 in Patients With Advanced Solid Tumors
NCT05434234
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Therapeutic Areas
What is open in the MediLink Therapeutics (Suzhou) Co. pipeline
6 recruiting of 7 indexed (86% open).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (3 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MediLink Therapeutics (Suzhou) Co.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 86% open enrollment, not the therapeutic-area sidebar.
MediLink Therapeutics (Suzhou) Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 86% open enrollment (± trial volume)
- Johnson & Johnson Enterprise Innovation · 86% recruiting · 7 trials
- Centessa Pharmaceuticals (UK) Limited · 83% recruiting · 6 trials
- Meyer Children's Hospital IRCCS · 83% recruiting · 6 trials
- SystImmune · 83% recruiting · 6 trials
Related
What to do with this MediLink Therapeutics (Suzhou) Co. page
7 registered trials is a research-attention snapshot, not an endorsement of MediLink Therapeutics (Suzhou) Co. or any single study.
- 6 of MediLink Therapeutics (Suzhou) Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition MediLink Therapeutics (Suzhou) Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MediLink Therapeutics (Suzhou) Co. pipeline card: 7 registered trials from official public datasets.Report a data error.